Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

  Oxford, UK – 24 November 2020 – Blue Earth Diagnostics, a leading molecular imaging…

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

  BURLINGTON, Mass. and OXFORD, UK, October 20, 2020 – Blue Earth Diagnostics, a Bracco…

Blue Earth Diagnostics Announces Results from Early Clinical Experience with Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Men with Intermediate and High-risk Prostate Cancer

− Results related to Company’s investigational Phase 3 radiohybrid PSMA agent presented at the AUA2020…

Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social Care

Oxford, UK and BURLINGTON, Mass., May 1, 2020 – Blue Earth Diagnostics, a Bracco company focused…

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) with first commercial supply in Slovakia, Europe

Oxford, UK – April 21, 2020 – Blue Earth Diagnostics Ltd, a Bracco company focused on molecular…

Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer

− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging…

Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® (Fluciclovine F18) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

− ASCO 2020 Genitourinary Cancers Symposium and Radiation Oncology Summit:  ACRO 2020 − BURLINGTON, Mass.…

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in…

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in men…

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting

BURLINGTON, Mass. and OXFORD, UK, September 10, 2019 – Blue Earth Diagnostics, a Bracco company…